Sareum Holdings Plc engages in the discovery and development of drug candidates for the treatment of cancers and autoimmune diseases. Its drug discovery pipeline includes Chk1, TYK2, and Aurora+FLT3 kinases. The company was founded by Timothy John Mitchell, David Hugh Williams, and John Charles Reader on August 1, 2003 and is headquartered in Cambridge, the United Kingdom.